Amedica Corporation

Amedica Corporation is a medical technology company focused on developing and commercializing innovative spinal and orthopedic implants made from advanced materials. Founded in 1996 in Salt Lake City, US, Amedica Corporation specializes in orthopedic and spinal implants utilizing advanced ceramic technology. The company has undergone strategic pivots to enhance its product offerings and broaden market reach. The founder, Samanpriya Wickramasinghe, has a background in developing innovative medical solutions.

Amedica Corporation has raised a total of USD 20. 00 mn through multiple funding rounds, culminating in its most recent IPO in February 2014, where it sold 3. 5 million shares at an exit price of USD 5. 75, below the expected range of USD 8 to 10.

The company has been involved in 13 different deals to date. Amedica Corporation specializes in advanced spinal and orthopedic implants utilizing unique ceramic materials. Their product line includes spinal fusion devices and orthopedic implants designed to enhance patient outcomes and support the healing process. The technologies aim to provide reliable solutions that address specific clinical needs, showcasing a commitment to improving surgical performance and patient recovery.

The company's offerings have gained traction in the orthopedic market, appealing to healthcare providers looking for effective and durable implant solutions. In the most recent fiscal year 2024, Amedica Corporation reported revenues of USD 2. 89 mn, with an EBITDA of USD -12. 66 mn.

The company generates revenue primarily through direct sales of its products and strategic partnerships, facilitating a diverse client base that includes hospitals and surgery centers. Looking ahead, Amedica Corporation plans to innovate by launching new spinal and orthopedic products aimed at enhancing surgical efficacy and patient recovery, with anticipated releases over the next 2 years. The company is also focused on expanding its market presence in Europe and Asia by the end of 2025. The capital raised through the IPO in February 2014 will support these initiatives, enabling investments in research and development as well as targeted marketing efforts.